Cargando…
Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma
BACKGROUND: BRAF(V600) inhibitors have offered a new gateway for better treatment of metastatic melanoma. However, the overall efficacy of BRAF(V600) inhibitors has been lower than expected in clinical trials, and many patients have shown resistance to the drug’s effect. We hypothesized that somatic...
Autores principales: | Shull, Austin Y., Latham-Schwark, Alicia, Ramasamy, Poornema, Leskoske, Kristin, Oroian, Dora, Birtwistle, Marc R., Buckhaults, Phillip J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422312/ https://www.ncbi.nlm.nih.gov/pubmed/22912864 http://dx.doi.org/10.1371/journal.pone.0043369 |
Ejemplares similares
-
Somatic Mutations, Allele Loss, and DNA Methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) Gene Reveals Association with Early Age of Diagnosis in Colorectal Cancer Patients
por: Shull, Austin Y., et al.
Publicado: (2013) -
Frequent somatic MAP3K5 and MAP3K9 mutations in metastatic melanoma identified by exome sequencing
por: Stark, Mitchell S, et al.
Publicado: (2011) -
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
por: Nymark Aasen, Synnøve, et al.
Publicado: (2019) -
The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma
por: Zhao, Xiaobei, et al.
Publicado: (2019) -
Joint action of miR‐126 and MAPK/PI3K inhibitors against metastatic melanoma
por: Pedini, Francesca, et al.
Publicado: (2019)